Loading data for UNCY — first visit, this takes a few seconds.
Unicycive Therapeutics, Inc. (UNCY)
NasdaqCM: UNCY
· Real-Time Price · USD
5.16
-0.14 (-2.64%)
At close: Sep 03, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
Unicycive Therapeutics, Inc. (UNCY) Stock Price, Analysis & Data
-2.68% (1D)
| Bid | 3.71 |
| Market Cap | 141M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.2M |
| 1.78 | |
| -1.75 | |
| n/a | |
| 3.65 | |
| P/B (ttm) | 2.70 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 12, 2026 |
| Ask | 6.74 |
| Volume | 105,560 |
| Avg. Volume (20D) | 1,508,333 |
| Open | 5.24 |
| Previous Close | 5.30 |
| Day's Range | 5.12 - 5.24 |
| 52-Week Range | 3.71 - 8.74 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About UNCY
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial p...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 12, 2021
Employees 21
Stock Exchange NasdaqCM
Ticker Symbol UNCY
Website https://unicycive.com
Financial Performance
In 2025, Unicycive Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -26.56M, a decrease of -27.7%.
Financial StatementsEarnings Surprise
Unicycive Therapeutics has released their quarterly earnings on Aug 12, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.06 exceeds estimates by 0.27, with 88.00% YoY growth.
Unicycive Therapeutics, Inc. is scheduled to release its earnings on Nov 12, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2